Nicholas Vogelzang

Nicholas Vogelzang led the landmark EMPHACIS trial demonstrating the superiority of pemetrexed plus cisplatin over cisplatin alone in mesothelioma, establishing the pemetrexed-based regimen that became first-line standard of care for over 15 years. His contributions to mesothelioma chemotherapy defined the treatment backbone upon which subsequent immunotherapy advances were built. He has had a prolific career spanning genitourinary and thoracic oncology clinical research with contributions to multiple landmark trials. His work on pemetrexed transformed the landscape for mesothelioma patients who previously had limited systemic options.